CASE REPORT

Progression after spontaneous regression in lung large cell neuroendocrine carcinoma: Report of a curative resection

Kenji Tomizawa^{1,2}, Kenichi Suda¹, Toshiki Takemoto¹, Takuya Iwasaki¹, Masahiro Sakaguchi¹, Hiroyuki Kuwano² & Tetsuya Mitsudomi¹

1 Department of Surgery, Division of Thoracic Surgery, Kinki University, Osaka, Japan

2 Department of General Surgical Science, Graduate School of Medicine, Gunma University, Maebashi, Gunma, Japan

Keywords

Lung large cell neuroendocrine carcinoma; progression; spontaneous regression.

Correspondence

Tetsuya Mitsudomi, Department of Surgery, Division of Thoracic Surgery, Kinki University Faculty of Medicine, 377-2 Ohno-Higashi, Osaka-Sayama 589-8511, Japan. Tel: +81 72 366 0221 (ext. 3794) Fax: +81 72 368 3382 Email: mitsudom@surg.med.kindai.ac.jp

Received: 22 September 2014; Accepted: 27 October 2014.

doi: 10.1111/1759-7714.12201

Thoracic Cancer 6 (2015) 655-658

Abstract

We present the first reported case of lung large cell neuroendocrine carcinoma (LCNEC) with spontaneous regression followed by progression. An 85-year-old woman presented with a 2.8-cm nodule in the right upper lung lobe on chest computed tomography. After four months, the tumor decreased to 1.8 cm and remained unchanged in size for the next three months, but it grew to 8.6 cm and invaded the mediastinal fat tissue after approximately one year. Ultrasound echo-guided percutaneous biopsy revealed the tumor to be LCNEC. The patient underwent a right upper lobectomy with lymph node dissection. She had a good postoperative course with no complications. Physicians and surgeons should be aware that radiographic regression of a pulmonary nodule does not necessarily exclude the possibility of lung cancer.

Introduction

Spontaneous regression of a malignancy is defined as the partial or complete disappearance of malignant disease without any medical treatment.¹ This phenomenon is extremely rare, with an estimated incidence of less than one in 60 000–100 000 cases.¹

Spontaneous regression has most often been noted in malignant melanoma (0.22–0.27%), renal cell cancer (0.3–4.0%), low-grade non-Hodgkins's lymphoma (3.7–15%), chronic lymphocytic leukemia (3.7–15%), and neuroblastoma in children (10%).^{2,3} The phenomenon is extremely rare in non-small cell lung cancer (NSCLC), and only two of the 176 tumors with spontaneous regression reported by Cole were lung cancer (1 squamous cell carcinoma and 1 undifferentiated).¹ We observed a rare and interesting case of lung large cell neuroendocrine carcinoma (LCNEC) that regressed spontaneously, then progressed rapidly.

Case report

An 85-year-old woman with a history of smoking presented with an abnormal shadow on chest X-ray, which was performed as part of a pre-operative evaluation for osteoarthritis of the knee in December 2012. A chest computed tomography (CT) scan revealed a 2.8 cm nodule in the right upper lung lobe (Fig 1a) and fluorodeoxyglucose–positron emission tomography (FDG-PET) showed uptake only within the nodule. Although transbronchial lung biopsy (TBLB) was negative, cytology of bronchoalveolar lavage fluid from the right upper bronchi showed atypical cells suspicious for malignancy.

The patient was referred to our hospital for curative pulmonary resection in March 2013. Her physical examination was unremarkable, and her blood examination, including tumor markers, showed anemia with a hemoglobin value of 10.2 mg/dL. The cause of the anemia was not clear despite scrutiny. In April 2013, the size of the tumor shadow

Thoracic Cancer **6** (2015) 655–658 © 2015 The Authors. Thoracic Cancer published by Tianjin Lung Cancer Institute and Wiley Publishing Asia Pty Ltd **655** This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.



Figure 1 Chest computed tomography scans showing the tumor shadow in the right upper lung lobe (in chronological order). The tumor shadow size and doubling times are presented. The patient underwent three biopsies. In July 2013, she was diagnosed with rheumatoid arthritis and began to receive glucocorticoid treatment. TBLB: transbronchial lung biopsy, US: ultrasound.

decreased from 2.8 to 1.8 cm (Fig 1b). We strongly suspected the tumor was benign rather than malignant and planned to perform a follow-up imaging examination. The tumor shadow remained unchanged for the next three months (Fig 1c). In July 2013, the patient was diagnosed with rheumatoid arthritis and began to receive glucocorticoid treatment. In January 2014, the tumor increased from 1.8 to 4.8 cm (Fig 1d) and a TBLB of the tumor was performed with suspicions of inflammatory disease or malignancy; however results of the TBLB were inconclusive. A chest CT scan was repeated in June 2014 and showed that the tumor shadow had further enlarged to 8.6 cm, with swelling of the mediastinal lymph nodes and suspected invasion of the superior vena cava and chest wall (Fig 1e). FDG-PET showed uptake within the tumor with a maximal standard uptake value of 23.6, but did not show uptake within the mediastinal lymph nodes. An ultrasound-guided biopsy of the tumor revealed a proliferation of tumor cells with large and irregular nuclei (Fig 2a). We diagnosed primary lung cancer, cT4N0M0, stage IIIA, according to the TNM (tumor node metastasis) Classification of Malignant Tumors (7th edition).

A right upper lobectomy with lymph node dissection in the hilum and right upper mediastinum was performed. Although the tumor had invaded the mediastinal fat tissue and parietal pleura, it did not invade the superior vena cava. The patient experienced a good postoperative course with no complications. On pathologic examination, the tumor was 7.5 cm in diameter and invaded the mediastinal fat tissue, but the lymph nodes did not show any evidence of metastasis. The histopathological results were similar to those from the biopsied tissue, and we diagnosed lung LCNEC, pathological stage IIIA (T4N0M0), based on immunohistochemical studies. The tumor was positive for synaptophysin, thyroid transcription factor-1, and cytokeratin 7, and was negative for chromogranin, CD56, and p63 (Fig 2b–d). The patient did not receive postoperative cytotoxic chemotherapy because of her own request and her advanced age.

Discussion

Our patient presents the first reported case of lung LCNEC with spontaneous regression. Furthermore, there have been no reports of spontaneous regression followed by rapid progression in primary lung cancer. To the best of our knowledge, 25 NSCLC tumors with spontaneous regression have been previously reported, including reviews by Kappauf *et al.*³ and Haruki *et al*⁴ (Table 1).^{3–8,10} Among these cases, 15 tumors were squamous cell carcinomas, eight were adenocarcinomas, three were large cell carcinomas, and one was NSCLC.

In our case, the tumor spontaneously regressed and subsequently showed rapid progression after the initiation of



Figure 2 (a) Biopsy tissue. The tumor showed a proliferation of tumor cells with large and irregular nuclei and necrosis (hematoxylin and eosin [H&E] stain, \times 200). (**b**–**d**) Surgical resected tissue. The histopathological findings from were similar to that from the biopsy tissue (**b**: H&E stain, \times 40 and **c**: H&E stain, \times 400, respectively). (**d**) We diagnosed a large cell neuroendocrine carcinoma based on immunohistochemical study; the tumor was positive for synaptophysin.

glucocorticoid treatment. Although several possible mechanisms of spontaneous regression have been presented, the details remain unclear.^{1,3} Among the proposed mechanisms, immunological activation may be one of the more reasonable. Infiltration with CD8-positive lymphocytes⁴ and a high degree of natural killing activity¹¹ have been reported within malignant tissues. If immunological activation was involved with the spontaneous regression of the tumor in our case, it may be reasonable to surmise that immunosuppression from glucocorticoid treatment could have affected the rapid progression of the tumor. However, it was difficult to fully evaluate the reasons for spontaneous regression in this case because blood and tissue samples were not available from the time of spontaneous regression.

Conclusion

This is the first report of spontaneous regression followed by progression in lung LCNEC. Physicians and surgeons should be aware that the radiographic regression of a pulmonary nodule does not necessarily exclude the possibility of lung cancer.

Acknowledgments

We wish to thank Takao Sato, M.D. (Department of Pathology, Kinki University Faculty of Medicine) for his helpful suggestions regarding the pathological findings.

 $\label{eq:table_$

1 Blades <i>et al</i> .† 1954 59/M SC)
2 Boyd <i>et al</i> .† 1966 56/M AI)
3 Margolis <i>et al</i> .† 1967 58/M AI)
4 Emerson <i>et al</i> .†‡ 1968 63/M SC)
5 Bell <i>et al</i> .† 1970 37/M SC)
6 Smith et al.† 1971 59/M SC)
7 Smith et al.† 1971 43/M SC)
8 Depierre <i>et al.</i> † 1984 57/M SC)
9 Kato et al.‡ 1986 55/F SC)
10 Sperduto <i>et al.</i> ‡ 1988 61/M SC)
11 Papac et al.† 1990 62/F Al)
12 Kappauf <i>et al.</i> ³ 1997 61/M AI)
13 Leo et al.‡ 1999 59/M LC	С
14 Saito <i>et al.</i> ‡ 1999 59/M AI)
15 Cafferata et al.‡ 2004 68/M AI)
16 Kato <i>et al</i> .‡ 2005 60/M AI)
17 Pujol <i>et al.</i> ⁵ 2007 75/F SC)
18 Moriyama <i>et al.</i> ‡ 2008 45/M LC	С
19 Gladwish <i>et al.</i> ⁶ 2010 81/F SC)
20 Haruki <i>et al.</i> ⁴ 2010 69/F AI)
21 Mizuno <i>et al.</i> ⁷ 2011 62/M LC	С
22 Furukawa et al. ⁸ 2011 56/M SC)
23 Choi et al. ⁹ 2013 71/M SC)
24 Hwang <i>et al.</i> ¹⁰ 2013 62/M NS	SCLC
25 Present case 2014 86/F LC	NEC

Literature reviews previously published by †Kappauf et al.³ and ‡Haruki et al.⁴ are included. AD, adenocarcinoma; F, female; LCC, large cell carcinoma; LCNEC, large cell neuroendocrine carcinoma; M, male; NSCLC, non-small cell lung cancer; SQ, squamous cell carcinoma.

Disclosure

No authors report any conflict of interest.

References

1 Cole WH. Efforts to explain spontaneous regression of cancer. *J Surg Oncol* 1981; **17**: 201–9.

- 2 Challis GB, Stam HJ. The spontaneous regression of cancer. A review of cases from 1900 to 1987. *Acta Oncol* 1990; **29**: 545–50.
- 3 Kappauf H, Gallmeier WM, Wünsch PH *et al*. Complete spontaneous remission in a patient with metastatic non-small-cell lung cancer. Case report, review of the literature, and discussion of possible biological pathways involved. *Ann Oncol* 1997; **8**: 1031–9.
- 4 Haruki T, Nakamura H, Taniguchi Y *et al.* Spontaneous regression of lung adenocarcinoma: Report of a case. *Surg Today* 2010; **40**: 1155–8.
- 5 Pujol JL, Godard AL, Jacot W, Labauge P. Spontaneous complete remission of a non-small cell lung cancer associated with anti-Hu antibody syndrome. *J Thorac Oncol* 2007; 2: 168–70.
- Gladwish A, Clarke K, Bezjak A. Spontaneous regression in advanced non-small cell lung cancer. *BMJ Case Rep* 2010; 2010: bcr0720103147.
- 7 Mizuno T, Usami N, Okasaka T, Kawaguchi K, Okagawa T, Yokoi K. Complete spontaneous regression of non-small cell lung cancer followed by adrenal relapse. *Chest* 2011; **140**: 527–8.
- 8 Furukawa M, Oto T, Yamane M, Toyooka S, Kiura K, Miyoshi S. Spontaneous regression of primary lung cancer arising from an emphysematous bulla. *Ann Thorac Cardiovasc Surg* 2011; **17**: 577–9.
- 9 Choi SM, Go H, Chung DH, Yim JJ. Spontaneous regression of squamous cell lung cancer. *Am J Respir Crit Care Med* 2013; 188: e5–6.
- 10 Hwang ED, Kim YJ, Leem AY *et al.* Spontaneous regression of non-small cell lung cancer in a patient with idiopathic pulmonary fibrosis: a case report. *Tuberc Respir Dis* 2013; 75: 214–7.
- Ono K, Kikuchi M, Funai N, Matsuzaki M, Shimamoto Y. Natural killing activity in patients with spontaneous regression of malignant lymphoma. *J Clin Immunol* 1996; 16: 334–9.